Summaries for Patients |

Benefits of Losartan in Patients with Hypertension and Left Ventricular Hypertrophy but No Vascular Disease FREE

Ann Intern Med. 2003;139(3):I-28. doi:10.7326/0003-4819-139-3-200308050-00002
Text Size: A A A

What is the problem and what is known about it so far?

High blood pressure (hypertension) is a chronic condition that damages blood vessels and body organs. It increases the risk for heart attacks, heart failure, strokes, and kidney failure. Doctors use many types of antihypertensive drugs to treat high blood pressure. Although the drugs may reduce blood pressure to a similar extent, their ability to prevent complications of high blood pressure may vary.

Recently, a large study in hypertensive patients with thickened heart muscle (left ventricular hypertrophy) showed that treatment with losartan (an angiotensin II receptor–blocker drug) prevented strokes more than did treatment with atenolol (a β-blocker drug). The study included high-risk patients who already had blood vessel disease (vascular disease) and lower-risk patients without vascular disease. Many researchers wondered whether losartan worked well in the lower-risk patients.

Why did the researchers do this particular study?

To assess the benefits of losartan in patients with hypertension and left ventricular hypertrophy but no vascular disease.

Who was studied?

6886 hypertensive men and women 55 to 80 years of age. All patients had heart tracings that showed left ventricular hypertrophy. No patient had known vascular disease.

How was the study done?

The researchers randomly assigned 9193 patients to receive either losartan or atenolol. Of these patients, 6886 had no previous heart, brain, or peripheral vascular disease. The patients and their doctors did not know who received which drug. Patients' blood pressures were taken regularly. If blood pressure levels were greater than 140/90 mm Hg, higher doses of losartan or atenolol or additional antihypertensive drugs were used. Patients were followed for about 5 years. During that time, the researchers routinely checked for complications, such as heart attacks and strokes.

What did the researchers find?

The losartan and atenolol groups achieved similar blood pressure reductions, but most patients in both groups needed two to three drugs to control blood pressure. Fewer patients in the losartan group had strokes and developed diabetes. Similar numbers of patients in both groups had heart attacks. More patients in the atenolol group (10%) had drug-related side effects than did patients in the losartan group (6%).

What were the limitations of the study?

The study is a subgroup analysis of a larger study. Subgroup analyses typically decrease the ability to show differences between groups in some outcomes and increase the possibility of finding some false differences. Most patients (95%) were white, and findings may not apply to black people.

What are the implications of the study?

Lower-risk, white patients with hypertension and left ventricular hypertrophy but no vascular disease benefit more from losartan-based therapy than atenolol-based therapy.





Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).


Submit a Comment/Letter
Submit a Comment/Letter

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.


Want to Subscribe?

Learn more about subscription options

Related Articles
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.